Article Sidebar
Published:
Aug 29, 2023Keywords:
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Submission of a paper for publication implies the transfer of the copyright from the author(s) to the publisher upon acceptance. Investigational Medicinal Chemistry and Pharmacology is therefore the copyright holder after publication of an article, and published articles should not be used for commercial purpose without the written consent of the Editor-in-Chief.
Main Article Content
Catechin Derivatives from Parkia biglobosa Displayed Selective Cytotoxicity Towards Leukemia CCRF-CEM Cell Line and its P-Glycoprotein Expressing Subline CEM/ADR5000
Abstract
Background: Cancer chemotherapy is challenged by drug resistance of malignant cells. In the present work, we evaluated the cytotoxicity of four catechin derivatives, 4’-methylepigallocatechin (1), gallocatechin (2), epigallocatechin (3), epigallocatechin-3-O-gallate (4) against nine drug sensitive and multidrug resistant (MDR) cancer cell lines.
Methods: The resazurin reduction assay was used to evaluate the cytotoxicity of the compounds.
Results: Catechin derivatives 1-4 displayed selective cytotoxic effect with IC50 values below 90 µM on the leukemia CCRF-CEM cells and it drug resistant subline CEM/ADR5000. In contrast, no IC50 values could be measured in all 7 carcinoma cell lines tested. CEM/ADR5000 cells were much more cross-resistant to doxorubicin than to compounds 1-4.
Conclusions: Hence, the four compounds may serve as lead drugs for further derivatization and can be explored in more details for their possible use to treat leukemia.
